[go: up one dir, main page]

AR023542A1 - Pirazolbenzodiazepinas - Google Patents

Pirazolbenzodiazepinas

Info

Publication number
AR023542A1
AR023542A1 ARP000101817A ARP000101817A AR023542A1 AR 023542 A1 AR023542 A1 AR 023542A1 AR P000101817 A ARP000101817 A AR P000101817A AR P000101817 A ARP000101817 A AR P000101817A AR 023542 A1 AR023542 A1 AR 023542A1
Authority
AR
Argentina
Prior art keywords
pirazolbenzodiazepinas
pyrazolbenzodiazepines
cdfs
antiproliferatives
colon
Prior art date
Application number
ARP000101817A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR023542A1 publication Critical patent/AR023542A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/22—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Pirazolbenzodiazepinas que presentan la formula (1) y las sales farmacéuticamente aceptables de las mismas, en donde R1, R2, R3 y R4 son como se handefinido en la memoria, son inhibidores de quinasas dependientes de ciclina (CDFs), en particularCDK2 y son agentes antiproliferativos utiles en eltratamiento o control de los trastornos proliferativos celulares, en particular, tumores de mama, colon, pulmon y prostata.
ARP000101817A 1999-04-21 2000-04-18 Pirazolbenzodiazepinas AR023542A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13037099P 1999-04-21 1999-04-21

Publications (1)

Publication Number Publication Date
AR023542A1 true AR023542A1 (es) 2002-09-04

Family

ID=22444382

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101817A AR023542A1 (es) 1999-04-21 2000-04-18 Pirazolbenzodiazepinas

Country Status (33)

Country Link
US (3) US6440959B1 (es)
EP (1) EP1185529B1 (es)
JP (1) JP3746680B2 (es)
KR (1) KR100481757B1 (es)
CN (2) CN1279029C (es)
AR (1) AR023542A1 (es)
AT (1) ATE279413T1 (es)
AU (1) AU768667B2 (es)
BR (1) BR0009887A (es)
CA (1) CA2367704C (es)
CO (1) CO5170444A1 (es)
CZ (1) CZ20013738A3 (es)
DE (1) DE60014893T2 (es)
DK (1) DK1185529T3 (es)
ES (1) ES2228522T3 (es)
HK (1) HK1046278B (es)
HR (1) HRP20010742A2 (es)
HU (1) HUP0300318A3 (es)
IL (1) IL145764A0 (es)
JO (1) JO2248B1 (es)
MA (1) MA26782A1 (es)
NO (1) NO20015065D0 (es)
NZ (1) NZ514523A (es)
PE (1) PE20010054A1 (es)
PL (1) PL200933B1 (es)
PT (1) PT1185529E (es)
RU (1) RU2249593C2 (es)
SI (1) SI1185529T1 (es)
TR (1) TR200103016T2 (es)
TW (1) TW585866B (es)
WO (1) WO2000064900A1 (es)
YU (1) YU73101A (es)
ZA (1) ZA200108016B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6520951B1 (en) 1996-09-13 2003-02-18 Scimed Life Systems, Inc. Rapid exchange catheter with detachable hood
IL161692A0 (en) * 2001-11-13 2004-09-27 Dimensional Pharm Inc 14-benzodiazepine derivatives and pharmaceutical compositions containing the same
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
CA2515790C (en) * 2003-02-27 2012-11-27 Abbott Laboratories Heterocyclic kinase inhibitors
DE602005007623D1 (de) * 2004-10-13 2008-07-31 Hoffmann La Roche Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine
EP1940410A1 (en) * 2005-10-14 2008-07-09 F.Hoffmann-La Roche Ag Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo [3, 4.-b] [1, 4] benzodiazepine
EP2081921B1 (en) 2006-07-10 2010-09-08 PAION UK Limited Short-acting benzodiazepine salts and their polymorphic forms
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
BR112014019052A8 (pt) * 2012-02-02 2017-07-11 Senex Biotechnology Inc Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer
CN103288830A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-5H-吡咯并[2,1-c][1,4]-苯并二氮杂卓的方法
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
CN103288828A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-6H-吲哚并[2,1-c][1,4]-苯并二氮杂卓的方法
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
EP3535253A1 (en) * 2016-11-01 2019-09-11 H. Hoffnabb-La Roche Ag 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of cns related diseases
PT3447056T (pt) * 2016-12-13 2025-06-25 Transthera Sciences Nanjing Inc Composto inibidor de multicinases e forma cristalina e uso do mesmo
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en) * 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
CN113620949B (zh) * 2020-05-08 2025-05-09 药捷安康(南京)科技股份有限公司 抗肿瘤化合物的合成方法及其中间体
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses
EP4338741A1 (en) * 2021-05-10 2024-03-20 Transthera Sciences (Nanjing), Inc. Pharmaceutical composition and use of multi-kinase inhibitor
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024030399A2 (en) * 2022-08-02 2024-02-08 Lab1636, Llc Use of a gaba-a pam for reduction of tactile hypersensitivity
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071092A1 (en) * 1991-06-14 1992-12-15 Roger M. Freidinger 1,4-benzodiazepines with 5-membered heterocyclic rings
EP0929553B1 (en) 1996-10-02 2005-03-16 Novartis AG Pyrimidine derivatives and processes for the preparation thereof
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers

Also Published As

Publication number Publication date
US6916923B2 (en) 2005-07-12
TR200103016T2 (tr) 2002-04-22
ES2228522T3 (es) 2005-04-16
JP3746680B2 (ja) 2006-02-15
HK1046278B (zh) 2005-08-12
JP2002543081A (ja) 2002-12-17
BR0009887A (pt) 2002-01-22
CA2367704A1 (en) 2000-11-02
CO5170444A1 (es) 2002-06-27
EP1185529B1 (en) 2004-10-13
CA2367704C (en) 2008-06-17
DE60014893D1 (de) 2004-11-18
HRP20010742A2 (en) 2002-12-31
CN1196703C (zh) 2005-04-13
NO20015065L (no) 2001-10-18
ATE279413T1 (de) 2004-10-15
HK1046278A1 (en) 2003-01-03
CN1348455A (zh) 2002-05-08
KR100481757B1 (ko) 2005-04-11
US20040198976A1 (en) 2004-10-07
PL354405A1 (en) 2004-01-12
AU768667B2 (en) 2003-12-18
RU2249593C2 (ru) 2005-04-10
KR20010112435A (ko) 2001-12-20
CN1603314A (zh) 2005-04-06
HUP0300318A2 (hu) 2003-06-28
US6838558B2 (en) 2005-01-04
AU4748000A (en) 2000-11-10
CZ20013738A3 (cs) 2002-08-14
NO20015065D0 (no) 2001-10-18
MA26782A1 (fr) 2004-12-20
DK1185529T3 (da) 2005-02-07
DE60014893T2 (de) 2005-10-13
US6440959B1 (en) 2002-08-27
US20020183514A1 (en) 2002-12-05
ZA200108016B (en) 2003-03-26
PT1185529E (pt) 2005-02-28
EP1185529A1 (en) 2002-03-13
TW585866B (en) 2004-05-01
YU73101A (sh) 2004-05-12
PE20010054A1 (es) 2001-02-07
SI1185529T1 (en) 2005-02-28
JO2248B1 (en) 2004-10-07
WO2000064900A1 (en) 2000-11-02
NZ514523A (en) 2003-11-28
IL145764A0 (en) 2002-07-25
CN1279029C (zh) 2006-10-11
PL200933B1 (pl) 2009-02-27
HUP0300318A3 (en) 2004-11-29

Similar Documents

Publication Publication Date Title
AR023542A1 (es) Pirazolbenzodiazepinas
PA8537401A1 (es) Diaminotiazoles
TR200003206T2 (tr) İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları.
MX9201419A (es) Derivados de benzo isoxazol-piperidina.
AR024847A1 (es) 4-alquenil y 4-alquinil oxindoles, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento.
AR023777A1 (es) Nuevos compuestos
BRPI0409366A (pt) compostos de pirimido
DK0719558T3 (da) Ranolzin og beslægtede piperazin til anvendelse ved behandling af chocktilstande
FI955709L (fi) Indolokarbatsolijohdannaisten käyttö eturauhasen patologisten tilojen hoidossa
DE60134874D1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
FI970768A7 (fi) Kasvainten geeniterapiahoito endoteelisoluspesifisellä, solusyklistä r iippuvalla vaikuttavalla aineella
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
SE9900100D0 (sv) New compounds
ES2193508T3 (es) Ftalizinonas.
PT1242060E (pt) Tratamento da doenca metastatica
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
PT998460E (pt) Novos derivados de tetrazole
PT889886E (pt) Novas fenantridinas substituidas na posicao 6
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
MXPA04004372A (es) Derivados heterociclicos de glicinamida y su uso medico.
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
BR9813719A (pt) Agentes terapêuticos
TR200101745T2 (tr) 4,5-Azolo-oksindoller
DE69735479D1 (de) Metalloproteinase inhibitoren

Legal Events

Date Code Title Description
FA Abandonment or withdrawal